This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Mechanism of Action DosingDosing InformationDose AdjustmentsDrug Interactions Trial Design & EfficacyTrial DesignEfficacySafety Profile & Tolerability  Support & ResourcesFrequently Asked QuestionsEducational ResourcesHCP Experience VideosNICE GuidanceEligible patient identification resources

Prescribing Information for PAXLOVID (nirmatrelvir / ritonavir) can be found here. Adverse event reporting information can be found at the bottom of the page.

Paxlovid has a Conditional Marketing Authorisation in the United Kingdom. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.

SystmOne Searches, Alerts and Referral Form
The clinical system resources and guide have been developed by Oberoi Consulting and Pfizer Limited and has been provided to the Department of Health and Social Care as part of a package deal associated with the procurement of Paxlovid.
Install the SystmOne Resources Suite: 

Before downloading this promotional resource please ensure you have fully read and understood the SystmOne Resources Installation Guide which you can find below. Please only download this resource if your practice uses SystmOne software. The download may take up to 15 minutes.
Click to download SystmOne ResourcesLoading
SystmOne Resources Installation Guide: 

Please read the below installation guide for a full overview of each functionality and installation instructions:








Intended for UK HCPs only. 

Click to download user guideLoading
Loading
The resource suite contains 3 functionalities:

Search


A search identifying individual cohorts of patients at the highest risk of severe COVID-19 as defined in line with NICE recommendations

Alert


Sends a real-time notification to clinicians when a high risk patient's record is opened and a consultation started, informing HCPs that the patient may be at risk of severe COVID-19 progression.  

Refer


A referral form that sits within the clinical system and includes a number of fields that will pre-populate with the patient's information and medical summary. This may make it easier for clinicians to refer high-risk patients for COVID-19 treatment services for review of their eligibility or treatment. 

These resources may support you with:

  • Quickly and easily identifying patients at high-risk of severe COVID-19.
  • Communicating key information with your high-risk patients.
  • Reducing the admin burden of identifying and referring potentially eligibile high-risk patients.


Why is it important to identify and communicate with high-risk patients?

  • NICE have identified that a potential 15 million patients will be at high risk of developing severe COVID-19 symptoms and may be eligible for treatment1.
  • Early treatment may help limit the impact of disease on patients and potentially alleviate pressure on the NHS, such as reducing hospital bed occupancy2,3.
  • Central communications to these patients have now been stopped so it is important that healthcare services communicate effectively with high-risk patients.

NICE guidelines recommend PAXLOVID as a first-line option for mild-moderate COVID-19 in eligible high-risk adult patients1.

These tools and supporting materials should not be used to replace clinical, medical judgement, advice, diagnosis or treatment of any health condition. Each patient should be individually assessed for the most appropriate course of action. Refer to the relevant SmPC and local or national guidance to support decision making. 

*Links to a third-party-website (outside of Pfizer). Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. Pfizer accepts no responsibility for the content or services of the linked site.


References: 

1. ©NICE [2024] TA878: Available from https://www.nice.org.uk/guidance/ta878.* All rights reserved. Subject to Notice of rights. 
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication (Accessed November 2024).
2GOV.UK. COVID-19 hospital activity. Available at: https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity * (Accessed November 2024)

3. Data on file. Pfizer Inc. Excerpts from Full Clinical Study Report for EPIC-HR and Core Data Sheet. February 2024.


PP-C1D-GBR-0359
January 2025

Adverse Events
 

Adverse Events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-C1D-GBR-0535. January 2025
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024.

YesNo
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​